CORT · Corcept Therapeutics Incorporated Q2 FY2026 earnings call record财报电话会记录

“The risks and uncertainties that may affect our forward-looking statements are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q, which are available at the SEC's website.”

“Our revenue in the second quarter of 2026 was $256.1 million, a 32% increase over the prior year period.”

“We expect growth to continue and have increased our 2026 revenue guidance to a range of $1.1 billion to $1.2 billion.”

“Net income was $43 million in the second quarter of 2026, compared to net income of $35 million in the prior year period.”

“Our cash and investments at June 30 were $545 million.”

“Our Cushing's syndrome business continues to experience strong demand.”

“MOMENTUM screened more than 1,000 patients with high blood pressure that was not controlled despite concurrent use of three or more antihypertension medications, a condition known as resistant hypertension, and found that 27% of these patients had hypercortisolism.”

“We expect this trend to continue, propelling our current Cushing's Syndrome business to at least $2 billion in annual revenue by the end of this decade.”

“With the addition of relacorilant, we expect that our Cushing's Syndrome annual revenue will grow to between $3 billion and $5 billion in 2020.”

“Patients treated with LIFYORLI and nab-paclitaxel chemotherapy experienced a 35% reduction in their risk of death, a hazard ratio of 0.65, compared to patients treated with nab-paclitaxel alone.”

“How much of this is clearing up of the backlog from the pharmacy transition versus capacity growth that you currently have gained with the new pharmacy on board?”

“You're talking about roughly about a week of demand that they keep on hand.”